CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 40 enrolled
Drug / intervention
Tetracycline slurry +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06695559
NCT06695559Phase 4Completed

Non Surgical Treatment of Peri-implantitis Using an Oscillating Chitosan Brush With Adjunctive Tetracycline Slurry: A Randomized Clinical Trial

Aristotle University Of Thessaloniki·interventional·Posted Nov 19, 2024·Updated Jan 27, 2026

In Brief

A Phase 4 clinical trial evaluating Labrida Bioclean and Tetracycline slurry for Periimplantitis and Periimplant Diseases. Completed, enrolled 40 participants across 1 site.

Detailed Summary

Aim: The aim of this prospective, randomized, parallel arm, blind clinical trial is to compare the clinical and radiographic outcomes following non-surgical treatment of mild peri-implant defects using Labrida Bioclean with or without the application of tetracycline slurry. Research Hypothesis: The hypothesis is that the adjunctive application of tetracycline slurry will enhance the clinical and radiographic results of non-surgical treatment of mild peri-implant defects (defined as peri-implant bone loss 3-6 mm with pocket depths 6 mm or deeper) with Labrida Bioclean. Probing pocket depth (PPD) reduction will be the primary outcome, whereas clinical attachment level (CAL), radiographic bone fill (RBF), recession depth (REC), modified bleeding index (mBI), presence of plaque (PL) , suppuration on probing (SUP) and Matrix Metalloproteinase-8 (MMP-8) levels on peri-implant sulcus fluid (PISF) will constitute the secondary outcome measures. Groups: Active comparator group: Debridement with Labrida Bioclean Experimental group: Debridement with Labrida Bioclean and irrigation with tetracycline slurry At the end of the treatment procedure patients will be given oral hygiene instructions and specifically patients of the experimental group will be instructed to refrain from oral hygiene for 24 hours before initiating oral hygiene. 1 month after therapy patients will be re-evaluated as a mean of PPD, CAL, REC, mBI, PL, SUP measurements and levels of MMP-8 on PISF. 3 months after therapy will be re-evaluated for second time as in the 1 month re-evaluation. Furthermore, treatment will be repeated as it was randomized on baseline. On 6 month re-evaluation PPD, CAL, REC, mBI, PL, SUP measurements will be made and also a periapical x-ray will be taken to compare the peri-implant bone level with the respective bone level on the x-ray of the baseline. On all of these appointments oral hygiene instructions and motivation will be given to the patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGreece
Collaborators--

Timeline

Phase 4CompletedFinished
202420252026
First PostedNov 19, 2024
Enrollment StartFeb 5, 2024
Primary CompletionMay 5, 2025
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 1.6 years ago

Interventions

Labrida Biocleanother

Debridement on the active comparator group will be implemented on the implant surface with Labrida Bioclean (i.e. the chitosan brush).

Tetracycline slurrydrug

On the experimental group debridement of the implant surface will be carried out with Labrida Bioclean and thereafter irrigation of the periimplant sulcus with tetracycline slurry will take place.